PT-141 (Bremelanotide)

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that acts as an agonist at melanocortin receptors MC3R and MC4R in the central nervous system — specifically the hypothalamus and limbic system. Bremelanotide is approved in the United States under the brand name Vyleesi for a specific type of acquired, generalised hypoactive sexual desire disorder (HSDD) in certain premenopausal women.

• Sexual desire

  • Activates melanocortin pathways involved in sexual motivation and desire.
  • May improve sexual desire in appropriately selected women with the condition for which it is approved.

• Sexual arousal

  • Influences central nervous system pathways associated with sexual arousal.
  • Its effects vary between individuals and do not guarantee increased arousal.

• Sexual function

  • Has been studied for certain sexual-function concerns.
  • Evidence and approved uses differ by population and indication.

• Central nervous system activity

  • Acts on melanocortin receptors involved in several physiological processes.
  • Works differently from medicines that directly increase genital blood flow.

• Target pathways involved in sexual desire
• Support treatment of a specific sexual-desire disorder when clinically appropriate
• Explore central nervous system mechanisms involved in sexual arousal

PT-141 activates melanocortin receptors, including MC4R, in the central nervous system, influencing brain pathways associated with sexual desire and modulating signalling involved in sexual motivation and arousal. Unlike PDE5 inhibitors such as sildenafil and tadalafil, which act peripherally on vascular smooth muscle, it operates centrally on the neural circuits governing sexual function.

FDA approval followed in 2019, when Vyleesi was licensed for hypoactive sexual desire disorder in premenopausal women, making bremelanotide one of the few peptides with full FDA approval. Research has demonstrated efficacy in both male and female sexual dysfunction, with effects mediated through dopaminergic and oxytocinergic pathways downstream of MC4R activation.

Bremelanotide is a prescription medicine in the United States and is approved only for a specific diagnosis in certain premenopausal women. A medical assessment is advised before considering any compound that acts on the central nervous system; ask a qualified professional to review your medicines and medical history first.

• Certain premenopausal women: those diagnosed with acquired, generalised HSDD that causes significant distress and is not primarily explained by another medical condition, relationship problems or medication effects
• People with sexual-desire concerns: those seeking a medical assessment to identify possible hormonal, psychological, medication-related or other contributing factors

Its effectiveness is not established for every type of sexual dysfunction, for postmenopausal women, or for improving sexual performance in people without a diagnosed condition.

No self-directed cycle is recommended. Bremelanotide is approved only for a specific diagnosis, so a qualified professional should confirm suitability, dose and interaction checks before any use.

Reconstitution: add 3 ml of bacteriostatic or sterile water. Use sterile single-use equipment and needles, do not share a cartridge, and ask a qualified professional to review the intended route and handling before use.

Follow the manufacturer’s label for the exact formulation, temperature range and expiry before and after opening or mixing. Request these instructions before ordering if missing. Do not assume a universal 30-day shelf life; keep away from heat and light and out of children’s reach. Ask for advice after any temperature excursion.